Brain Cancer

- IDH mutant astrocytoma
- IDH mutant glioma
- Brain metastases
- Brain metastases, not otherwise stated
- Meningioma
- Recurrent high-grade radiation-relapsed meningioma
- Peripheral nerve sheath tumors
- Peripheral nerve sheath tumors

**ETCTN Trials by Disease/ Treatment Area: Brain Cancer**

- **10218**: A Phase Ib Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
- **10129**: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 Cohorts: glioma, cholangiocarcinoma, other solid tumors)
- **9979**: Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
- **9952**: Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)
- **10186**: A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
- **10220**: A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

**NOTE**: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: August 18, 2020